TGF-β / Smad Signaling
The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
- B1287 Ro 31-8220Target: PKCSummary: pan-PKC inhibitor
- B2191 Dequalinium ChlorideTarget: PKC|Calcium-Activated Potassium (KCa) ChannelsSummary: anti-tumor agent and PKC inhibitor
- B2287 LY3649471 CitationSummary: inhibitor of TGF-β type I receptor kinase domain
- B2288 PirfenidoneSummary: TGF-β production inhibitor
- A8192 Staurosporine6 CitationSummary: Protein kinase inhibitor, potent and cell permeable
- B3392 GSK269962ATarget: ROCK|RSK|MSKSummary: ROCK inhibitor
- A8830 ZIP (SCRAMBLED)Summary: PKMζ inhibitor
- B3686 DMH-1Target: BMP and Other Activin ReceptorsSummary: Selective BMP ALK2 receptor
- B3687 LDN-212854Summary: BMP receptor inhibitor,potent and selective
- B3688 ML347Target: BMP and Other Activin ReceptorsSummary: BMP receptor inhibitor,potent and selective